All Stories

  1. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2017, Dove Medical Press

    Michael Humphries

  2. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2016, Dove Medical Press

    giovanni bader, Michael Humphries, Claus Vogelmeier

  3. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2015, Dove Medical Press

    Michael Humphries

  4. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2015, Dove Medical Press

    Michael Humphries

  5. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2015, Taylor & Francis

    Michael Humphries